Analyzing Zenas Biopharma (ZBIO) and The Competition

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Zenas Biopharma to related companies based on the strength of its risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Profitability

This table compares Zenas Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.5%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.1% and pay out 116.1% of their earnings in the form of a dividend.

Valuation and Earnings

This table compares Zenas Biopharma and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.57
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-55.89

Zenas Biopharma’s competitors have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Zenas Biopharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	824	2262	4730	56	2.51

Zenas Biopharma currently has a consensus target price of $40.00, suggesting a potential upside of 339.08%. As a group, “Biotechnology” companies have a potential upside of 46.12%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Zenas Biopharma is more favorable than its competitors.

Institutional and Insider Ownership

29.3% of shares of all “Biotechnology” companies are held by institutional investors. 22.5% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Zenas Biopharma beats its competitors on 7 of the 13 factors compared.

Zenas Biopharma Company Profile

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.